GoodRx sells shares in IPO above target range – source
NYSE president: Pipeline for IPOs, SPACs, and direct listings ‘incredibly strong’
NYSE President Stacey Cunningham provides insight into record market highs, delisting China firms, and the IPO market.
NEW YORK - GoodRx Holdings Inc on Tuesday priced its initial public offering (IPO) at $33 per share, above its target range, according to a person familiar with the matter.
Continue Reading Below
The U.S. online prescription drug platform had planned to sell 34.6 million shares in its IPO at a target range of $24 and $28 per share.
GoodRx did not immediately respond to a request for comment.
CLICK HERE TO READ MORE STORIES ON FOX BUSINESS
China to suspend imports of aquatic products from Norwegian firm after coronavirus detected
SHANGHAI (REUTERS) – China said it will suspend imports of aquatic products from Norwegian company Gadus Njord for one week as it detected the coronavirus in a product’s outer package, according to a customs statement on Wednesday morning (Sept 23).
Imports will automatically resume after one week, the customs statement added.
Sign up for the ST Asian Insider newsletter to get exclusive insights into Asia from our network of overseas correspondents.
Covid-19 grant extended, but eligibility rules revised
A grant that helps Singaporeans and permanent residents who have lost their jobs or suffered significant income loss due to the pandemic will be extended to the end of this year, but with revised eligibility criteria.
From Oct 1, those applying for the Covid-19 Support Grant (CSG), which provides up to $800 a month for three months, should also not own more than one property.
Those who are unemployed and applying for the CSG must also show job search or training efforts to qualify, said the Ministry of Social and Family Development.
Live Updates: 2020 Presidential race heating up six weeks before election
Impact of Supreme Court vacancy on 2020 election
Senate Majority Leader Mitch McConnell vows President Trump’s Supreme Court nominee will receive a vote in the Senate; reaction and analysis from Fox News contributor Marc Thiessen.
The campaign trail is starting to heat up between President Trump and Joe Biden, a week before the first presidential debate is scheduled to take place in Cleveland and just six weeks before Election Day.
Follow below for the latest updates on the 2020 Presidential Election. Mobile users click here:
Fujifilm to Seek Approval for Covid Drug After Positive Trial
Fujifilm Holdings Corp. said it would seek regulatory approval to market a flu drug as a treatment for Covid-19 after a trial in Japan showed that it helped patients with mild cases of the disease recover faster.
The company plans to apply for regulatory approval as early as October, it said in a statement Wednesday. Fujifilm’s stock rose as much as 4.6% in Tokyo trading after the announcement.
In a trial of 156 patients, those who took the drug called Avigan recovered in an average of 11.9 days, compared to 14.7 days for the placebo group, said the statement. No safety concerns emerged in the trial.
Avigan, also known as favipiravir, has been promoted heavily by the Japanese government and donated to over 80 countries in recent months, even before clinical trials were completed.
The drug, which has the potential to cause birth defects because of its mechanism of stopping RNA replication, is currently approved for use in Japan to treat novel influenza.
BOJ will continue experiments for issuing CBDCs – Kuroda
TOKYO, Sept 23 (Reuters) – The Bank of Japan will work closely with overseas central banks in conducting experiments on issuing its own digital currency in the future, BOJ Governor Haruhiko Kuroda said on Wednesday.
“The BOJ does not have any plan to issue central bank digital currencies (CBDC) now,” Kuroda said in an online meeting with business leaders in Osaka, western Japan.
“But technology progresses rapidly, which means the public’s request for us to issue CBDCs could heighten sharply,” he said. “It’s therefore important for us to be ready with close cooperation with overseas central banks.”
Philippines Reopens Tourism Hotspot Boracay to More Locals
The Philippines is reopening Boracay island, one of its main tourist attractions, to more visitors starting Oct. 1 as itbanks on locals to revive its pandemic-hit tourism sector.
Tourists from areas under general community quarantine, including the capital Manila, will be allowed on the island next month as long as they have tested negative from the coronavirus and have pre-booked accommodations, Tourism Undersecretary Benito Bengzon said at a televised briefing on Wednesday.
The reopening of Boracay, which was recently open only to residents and visitors from neigboring provinces, comes as the nationpushes for further economic activity despite having the most infections in Southeast Asia. The central Philippine island famous for its powdery white sand beaches drew 2 million tourists last year mainly from China and South Korea.
The Department of Tourism said earlier this month that itforesees international tourism, mainly from the region, to resume by the second half of 2021. Tourism accounted for almost 13% of the Philippines’ economic output last year.